Login / Signup

The Management of Mild Pulmonary Hypertension in Clinical Practice.

Katarina ZederFrank E HarrellGabor KovacsBradley A Maron
Published in: Annals of the American Thoracic Society (2024)
The definition of pulmonary hypertension (PH) has been revised recently, with the mean pulmonary artery pressure (mPAP) threshold (assessed by right heart catheterization) reduced from ⩾25 mm Hg to >20 mm Hg. This change reflects the mPAP upper limit of normal and a lower limit that is independently associated with adverse outcomes. To improve the specificity of diagnosing pathogenic increases in mPAP, however, a diagnosis of precapillary PH now also includes pulmonary vascular resistance >2.0 Wood units (WU) (lowered from >3.0 WU). These changes are positioned to capture approximately 55% more patients with PH. Because all clinical trials showing a benefit of pulmonary vasodilator therapy in precapillary PH used the classical hemodynamic definition, the approach to the diagnosis and management of patients with mild PH (i.e., mPAP 21-24 mm Hg and pulmonary vascular resistance 2-3 WU) requires particular consideration. Here, we use a question/answer format to discuss key areas in the management of mild PH, including practical information tailored to clinicians without training in PH.
Keyphrases
  • pulmonary hypertension
  • pulmonary artery
  • pulmonary arterial hypertension
  • clinical trial
  • stem cells
  • coronary artery
  • fluorescent probe
  • atrial fibrillation
  • open label
  • study protocol
  • replacement therapy